<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567307</url>
  </required_header>
  <id_info>
    <org_study_id>WFUBMC-IRB00004134</org_study_id>
    <secondary_id>SLCTR/ 2007/012</secondary_id>
    <nct_id>NCT00567307</nct_id>
  </id_info>
  <brief_title>Polypill For Prevention of Cardiovascular Disease</brief_title>
  <official_title>The Feasibility of a Polypill Clinical Trial for Primary Prevention of Cardiovascular Disease: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Hospital of Sri Lanka</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to provide data on the feasibility of conducting a large
      clinical trial on the polypill (combination of aspirin, angiotensin converting enzyme
      inhibitor, thiazide diuretic, and statin) for primary prevention of cardiovascular disease
      (CVD). We hypothesized that A &quot;polypill&quot; comprising the aforementioned four components would
      significantly reduce the estimated 10-year total CVD risk score with high adherence and no
      significant increase in adverse effects compared to the standard practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, parallel-group, randomized clinical trial comparing a Polypill to
      Standard Practice (defined as usual care administered to patients with similar conditions).
      Approximately 200 participants will be recruited from three sites in Sri Lanka: The National
      Hospital of Sri Lanka, Colombo; Teaching Hospital, Kegalle, and Teaching Hospital, Kandy.
      Subsequent to granting written informed consent, patients will undergo screening and baseline
      evaluation to confirm eligibility, followed by randomization to the Polypill or to the
      Standard Practice study arm. Patients receiving either intervention will return for a total
      of three monthly clinic visits.

      Physician acceptability will be evaluated through a five-question survey will be mailed to a
      random sample of physicians from the participating clinical sites and to the Council of
      General Practitioners in Sri Lanka.

      Patient acceptability will be measured in participants who will complete the study as well as
      those who will be screened but not eligible
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of the Estimated 10-year Total Cardiovascular Risk Score</measure>
    <time_frame>Six months</time_frame>
    <description>Estimated 10-year CVD total risk score were calculated in the field centers and in the Coordinating Center from the measures of blood pressure and total cholesterol and from the medical history data collected during each visit using the WHO CVD prediction chart. The estimated 10-year CVD total risk calculated by the Coordinating Center were used for analysis. the score is based on systolic blood pressure and total cholesterol measures as well as on medical history data (monthly). Each one of these risk factors is assigned a point in the score and then linked to a table that mention the calculated CVD risk</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>The Red Heart Pill 2b (Polypill) (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Polypill is composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Practice Group (B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Red Heart Pill 2b (Polypill)</intervention_name>
    <description>Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)</description>
    <arm_group_label>The Red Heart Pill 2b (Polypill) (A)</arm_group_label>
    <other_name>Polypill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Practice</intervention_name>
    <description>Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions</description>
    <arm_group_label>Standard Practice Group (B)</arm_group_label>
    <other_name>Usual care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Estimated 10-year total CVD risk score &gt; 20%. The total CVD risk assessment will be
             based on the recently developed WHO CVD risk prediction charts

          -  No contraindication for treatment with aspirin, angiotensin converting enzyme
             inhibitors, low-dose diuretics, or statins

          -  Informed consent given

        Exclusion Criteria:

          -  Patients with established angina pectoris, coronary heart disease, myocardial
             infarction, transient ischemic attacks, stroke, peripheral vascular disease, coronary
             revascularization and/or carotid endarterectomy Left ventricular hypertrophy (on ECG)
             or hypertensive retinopathy (grade III or IV)

          -  Patients with secondary hypertension

          -  Patients with diabetes type 1 or 2 with overt neuropathy or other significant renal
             disease.

          -  Known renal failure or impairment

          -  Atrial fibrillation

          -  ALT &gt; 1.5 times the upper limit of normal

          -  History of liver cirrhosis or hepatitis

          -  History of recent gastrointestinal bleeding (within the last year)

          -  Women in child bearing period

          -  History of life-limiting diseases or events

          -  Unwillingness to sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elsayed Z Soliman, MD, MSc, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shanthi Mendis, MD, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>World Heath Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Curt D Furberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The National Hospital of Sri Lanka</name>
      <address>
        <city>Colombo</city>
        <zip>Colombo10</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teaching (General) Hospital Kandy</name>
      <address>
        <city>Kandy</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teaching (General) Hospital Kegalle</name>
      <address>
        <city>Kegalle</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sri Lanka</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <results_first_submitted>October 24, 2016</results_first_submitted>
  <results_first_submitted_qc>October 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2016</results_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>The Polypill Group (Arm A)</title>
          <description>The Polypill Group (Arm A) received a Polypill composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide
Red Heart Pill 2b (Polypill): Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)</description>
        </group>
        <group group_id="P2">
          <title>Standard Practice Group (Arm B)</title>
          <description>Standard Practice
Standard Practice: Arm B received management of their CVD risk according to the usual care given to participants in similar conditions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>The Polypill Group (Arm A)</title>
          <description>The Polypill Group (Arm A) received a Polypill composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide
Red Heart Pill 2b (Polypill): Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)</description>
        </group>
        <group group_id="B2">
          <title>Standard Practice Group (Arm B)</title>
          <description>Standard Practice
Standard Practice: Arm B received management of their CVD risk according to the usual care given to participants in similar conditions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="216"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="7.4"/>
                    <measurement group_id="B2" value="59.0" spread="6.9"/>
                    <measurement group_id="B3" value="59.1" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.7" spread="17.3"/>
                    <measurement group_id="B2" value="165.7" spread="19.2"/>
                    <measurement group_id="B3" value="165.2" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="1.3"/>
                    <measurement group_id="B2" value="6.1" spread="1.3"/>
                    <measurement group_id="B3" value="5.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction of the Estimated 10-year Total Cardiovascular Risk Score</title>
        <description>Estimated 10-year CVD total risk score were calculated in the field centers and in the Coordinating Center from the measures of blood pressure and total cholesterol and from the medical history data collected during each visit using the WHO CVD prediction chart. The estimated 10-year CVD total risk calculated by the Coordinating Center were used for analysis. the score is based on systolic blood pressure and total cholesterol measures as well as on medical history data (monthly). Each one of these risk factors is assigned a point in the score and then linked to a table that mention the calculated CVD risk</description>
        <time_frame>Six months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>The Polypill Group (Arm A)</title>
            <description>The Polypill Group (Arm A) received a Polypill composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide
Red Heart Pill 2b (Polypill): Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)</description>
          </group>
          <group group_id="O2">
            <title>Standard Practice Group (Arm B)</title>
            <description>Standard Practice
Standard Practice: Arm B received management of their CVD risk according to the usual care given to participants in similar conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of the Estimated 10-year Total Cardiovascular Risk Score</title>
          <description>Estimated 10-year CVD total risk score were calculated in the field centers and in the Coordinating Center from the measures of blood pressure and total cholesterol and from the medical history data collected during each visit using the WHO CVD prediction chart. The estimated 10-year CVD total risk calculated by the Coordinating Center were used for analysis. the score is based on systolic blood pressure and total cholesterol measures as well as on medical history data (monthly). Each one of these risk factors is assigned a point in the score and then linked to a table that mention the calculated CVD risk</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="113.0"/>
                    <measurement group_id="O2" value="11.1" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Cumulative frequency of major side effects during the 3-month treatment period by study group among those who completed the study (99 in the polypill group and 104 in the standard practice)</time_frame>
      <desc>This is among those who completed the study (99 in the polypill group and 104 in the standard practice)</desc>
      <group_list>
        <group group_id="E1">
          <title>The Polypill Group (Arm A)</title>
          <description>The Polypill Group (Arm A) received a Polypill composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide
Red Heart Pill 2b (Polypill): Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)</description>
        </group>
        <group group_id="E2">
          <title>Standard Practice Group (Arm B)</title>
          <description>Standard Practice
Standard Practice: Arm B received management of their CVD risk according to the usual care given to participants in similar conditions</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="99"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="99"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="99"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="99"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Elsayed Z Soliman, Director of the Epidemiological Cardiology Research Center</name_or_title>
      <organization>Wake Forest School of Medicine, Winston Salem, NC</organization>
      <phone>336-716-8632</phone>
      <email>esoliman@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

